Nutriband replaces $2M credit line with $5M facility at 7% for AVERSA Fentanyl

NutriBand Inc.

Secured $5M credit line at 7% interest, maturing July 13, 2026, replacing prior $2M facility.
Funds for AVERSA™ Fentanyl FDA approval and commercial manufacturing via Kindeva Drug Delivery.
No conversion rights; advances contingent on starting Kindeva work related to NDA filing.
Interest payable annually each Dec 31 starting 2023; prepayment allowed without penalty.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

NutriBand Inc. amended a credit facility valued at $5,000,000 (effective 2023-07-13).

Action: amendment
Agreement: credit facility
Value: $5,000,000
Effective: 2023-07-13

Exact text from the filing

The Company on July 13, 2023 entered into an amended three-year $5,000,000 credit line facility (replacing the $2,000,000 facility that we had entered into on March 19, 2023), drawdowns under which bear interest at the rate of 7% per annum.

View on SEC.gov

Browse all material agreements →

NutriBand Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-056939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.